Abstract 2162P
Background
There is limited data on the quality of cancer information provided by ChatGPT and other artificial intelligence systems. In this study, we aimed to compare the accuracy of information about cancer pain provided by chatbots (chatGPT, perplexity, and chatsonic) based on the questions and answers contained in the the European Medical Oncology Association (ESMO) Patient Guide about cancer pain.
Methods
Twenty questions were selected from the questions available in the ESMO Patient Guide Cancer Pain. Medical oncologists with more than 10 years of experience compared responses from chatbots (ChatGPT, Perplexity, and Chatsonic) with the ESMO patient guide. The primary evaluation criteria for the quality of the responses were accuracy, patient readability, and stability of response. The accuracy of responses was evaluated using a three-point scale: 1 for accuracy, 2 for a mixture of accurate and incorrect or outdated data, and 3 for wholly inaccurate. The Flesch-Kincaid readability (FKr) grade was used to measure readability. Stability of responses was evaluated whether the model’s accuracy is consistent across different answers to the same question.
Results
Chatbots were more difficult to read than the ESMO patient guideline (FKr= 9.6 vs. 12.8, p= 0.072). Among the chatbots, perplexity had the easiest readability (FKr= 11.2). In the accuracy evaluation, the percentage of overall agreement for accuracy was 100% for ESMO answers and 96% for ChatGPT outputs for questions (k= 0.03, standard error= 0.08). Among the chatbots, the most accurate information was obtained with chatGPT.
Table: 2162P
Comparison of ESMO and chatbots in terms of readibility and accuracy
ESMO | Chatbots | ||||
ChatGPT | Perplexity | Chatsonic | p-value | ||
Readibility (FKr grade) | 9.6 Easily understood | 13.4 Difficult to read | 11.2 Fairly difficult to read | 13.9 Difficult to read | 0.072 |
Accuracy | %100 | %96 | %86 | % 90 | 0.037 |
Conclusions
The results suggest that ChatGPT provides more accurate information about cancer pain compared with other chatbots.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Gazi University Ethic Commitee.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2237P - Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial
Presenter: Nicolas Huyghe
Session: Poster session 07
2238P - Tebentafusp reprograms immunosuppressive tumor-associated M2 macrophages towards anti-tumoral M1 macrophages
Presenter: Josep M. Piulats
Session: Poster session 07
2239P - Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types
Presenter: Elia Segui Solis
Session: Poster session 07
2240P - Novel genetic markers associated with immune checkpoint inhibitor induced immune-related adverse events
Presenter: Ik Shin Chin
Session: Poster session 07
2241P - A novel 89Zr-anti-PD-1 immuno-PET-CT may predict response to PD-1 inhibitors and improve response assessment in a lung cancer murine model receiving immunotherapy
Presenter: Ander Puyalto
Session: Poster session 07
2242P - Engineering immune-cell targeting nanoparticles for precise delivery of loaded-cargo and enhanced immunotherapy efficacy
Presenter: Na Kyeong Lee
Session: Poster session 07
2243P - Immune-modulating magnetic nanoparticles to enhance the immune response for the treatment of breast cancer metastasis and recurrence
Presenter: Jaesung Lim
Session: Poster session 07
2244P - Anti CTLA-4 and PD-1 monoclonal antibodies increases systemic SDF-1 and galectin-3 levels through NLRP3 and MyD-88 pathways in preclinical models
Presenter: Vincenzo Quagliariello
Session: Poster session 07
2245P - Graphene oxide: A promising platform for delivery of cancer immunotherapy
Presenter: Sorayut Chattrakarn
Session: Poster session 07
2246P - Tumor-infiltrating lymphocites and gene expression across multiple cancer-types: A translational analysis from the SOLTI-1904-ACROPOLI study
Presenter: Elia Segui Solis
Session: Poster session 07